Issue 3/2012
Content (28 Articles)
Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice
Selwyn J. Hurwitz, Hongzheng Zhang, Sujin Yun, Thil D. Batuwangala, Michael Steward, Steve D. Holmes, Daniel Rycroft, Lin Pan, Mourad Tighiouart, Hyung Ju C. Shin, Lydia Koenig, Yuxiang Wang, Zhuo (Georgia) Chen, Dong M. Shin
A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors
Matthew G. Fury, Eric Sherman, Sofia Haque, Susan Korte, Donna Lisa, Ronglai Shen, Nian Wu, David Pfister
Evaluation of a formula for individual dosage of nedaplatin based on renal function
Shinya Sato, Hiroyuki Fujiwara, Tetsuro Oishi, Muneaki Shimada, Shizuo Machida, Yuji Takei, Hiroaki Itamochi, Mitsuaki Suzuki, Junzo Kigawa
An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
Cindy L. O’Bryant, Paul Haluska, Lee Rosen, Ramesh K. Ramanathan, Balaji Venugopal, Stephen Leong, Ramesh Boinpally, Amy Franke, Karsten Witt, Jeffry Evans, Chandra Belani, S. Gail Eckhardt, Suresh Ramalingam
Adjuvant therapy for resectable high-risk soft tissue sarcoma: feasibility and efficacy of a sandwich chemoradiotherapy strategy
Christian H. Brandts, Christiane Schulz, Normann Willich, Björn Steffen, Jendrik Hardes, Georg Gosheger, Winfried Winkelmann, Hubert Serve, Achim Heinecke, Wolfgang E. Berdel, Michael Thomas
Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells
Pei-Ming Chu, Li-Hsin Chen, Ming-Teh Chen, Hsin-I Ma, Tsann-Long Su, Pei-Chen Hsieh, Chian-Shiu Chien, Bo-Hua Jiang, Yu-Chih Chen, Yi-Hui Lin, Yang-Hsin Shih, Pang-Hsien Tu, Shih-Hwa Chiou
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma
Eun Mi Lee, Sun Young Rha, Jeeyun Lee, Kyong Hwa Park, Jin-Hee Ahn
Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys
Donald Jung, Lin Lin, Hailong Jiao, Xiaohong Cai, Jian-Xin Duan, M. Matteucci
Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data
Dong Hoe Koo, Seung-Il Park, Yong-Hee Kim, Jong Hoon Kim, Hwoon-Yong Jung, Gin-Hyug Lee, Kee Don Choi, Ho June Song, Ho Young Song, Ji Hoon Shin, Kyung-Ja Cho, Dok-Hyun Yoon, Sung-Bae Kim
Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells
C. L. King, S. Ramachandran, S. G. Chaney, L. Collins, J. A. Swenberg, K. E. deKrafft, W. Lin, L. Cicurel, M. Barbier
Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice
Liu Zhongfa, Ming Chiu, Jiang Wang, Wei Chen, Winston Yen, Patty Fan-Havard, Lisa D. Yee, Kenneth K. Chan
The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue
Patrizia Chiusolo, Sabrina Giammarco, Silvia Bellesi, Elisabetta Metafuni, Nicola Piccirillo, Daniela De Ritis, Sara Marietti, Sorà Federica, Luca Laurenti, Luana Fianchi, Stefan Hohaus, Leone Giuseppe, Simona Sica
In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues
Caroline Haglund, Anna Åleskog, Peter Nygren, Joachim Gullbo, Martin Höglund, Malin Wickström, Rolf Larsson, Elin Lindhagen
A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
L. Q. M. Chow, N. Blais, D. J. Jonker, S. A. Laurie, S. G. Diab, C. Canil, M. McWilliam, A. Thall, A. Ruiz-Garcia, K. Zhang, L. Tye, R. C. Chao, D. R. Camidge
miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP
Wei Zhu, Huaguo Xu, DanXia Zhu, Hui Zhi, Tongshan Wang, Jian Wang, Binghua Jiang, Yongqian Shu, Ping Liu
First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer
Vincent Chung, Elisabeth I. Heath, William R. Schelman, Brendan M. Johnson, Lyndon C. Kirby, Kerlin M. Lynch, Jeffrey D. Botbyl, Thomas A. Lampkin, Kyle D. Holen
A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer
M. G. Fakih, A. Groman, J. McMahon, G. Wilding, J. R. Muindi
Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors
Max E. Scheulen, Kaku Saito, Ralf A. Hilger, Bastian Mende, Christopher Zergebel, Dirk Strumberg
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Samuel R. Denmeade, Susan F. Slovin, Kathy Jelaca-Maxwell, Martha E. Vincent, Howard I. Scher, Michael J. Morris
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma
Iacopo Petrini, Monica Lencioni, Miriam Ricasoli, Mauro Iannopollo, Cinzia Orlandini, Filippo Oliveri, Carlo Bartolozzi, Sergio Ricci
Intrapleural paclitaxel for malignant pleural effusion from ovarian and breast cancer: a phase II study with pharmacokinetic analysis
Giuseppe Lombardi, Maria Ornella Nicoletto, Milena Gusella, Pasquale Fiduccia, Maurizia Dalla Palma, Andrea Zuin, Davide Fiore, Martin Donach, Vittorina Zagonel
Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects
Nianhang Chen, Lian Wen, Henry Lau, Sekhar Surapaneni, Gondi Kumar
ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
Guan Wang, Yao Zhan, Haiqing Wang, Wenhua Li
Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX
T. Mazard, M. Ychou, S. Thezenas, S. Poujol, F. Pinguet, A. Thirion, J. P. Bleuse, F. Portales, E. Samalin, E. Assenat
A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Heather A. Wakelee, Gary Middleton, David Dunlop, Rodryg Ramlau, Natasha Leighl, Desiree Hao, Arturo Lopez-Anaya, Petr Zatloukal, Charlotte D. Jacobs
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
Jordi Rodon, Charlotte D. Jacobs, Quincy Chu, Eric K. Rowinsky, Arturo Lopez-Anaya, Chris H. Takimoto, Heather A. Wakelee
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study
Joseph Chao, Timothy W. Synold, Robert J. Morgan Jr., Charles Kunos, Jeff Longmate, Heinz-Josef Lenz, Dean Lim, Stephen Shibata, Vincent Chung, Ronald G. Stoller, Chandra P. Belani, David R. Gandara, Mark McNamara, Barbara J. Gitlitz, Derick H. Lau, Suresh S. Ramalingam, Angela Davies, Igor Espinoza-Delgado, Edward M. Newman, Yun Yen
Pharmacokinetics of carboplatin in a hemodialysis patient with small-cell lung cancer
Mikako Hiraike, Yoichi Hiraki, Nobuhiro Misumi, Kiyonori Hanada, Yasuhiro Tsuji, Hidetoshi Kamimura, Yoshiharu Karube, Kosuke Kashiwabara